colorectal neoplasms

Summary

Summary: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Top Publications

  1. ncbi Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
    M M Borner
    Early Clinical Studies Group of The European Organization for Research and Treatment of Cancer, Belgium
    Eur J Cancer 38:349-58. 2002
  2. ncbi KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
    J H J M van Krieken
    Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500, HB, The Netherlands
    Virchows Arch 453:417-31. 2008
  3. doi Role of miR-143 targeting KRAS in colorectal tumorigenesis
    X Chen
    Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China
    Oncogene 28:1385-92. 2009
  4. pmc Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer
    Veronica Rodilla
    Institut d Investigació Biomèdica de Bellvitge Gran Via km 2 7, Hospitalet and Institut Municipal d Investigacions Mèdiques Hospital del Mar, Dr Aiguader 88, 08003 Barcelona, Spain
    Proc Natl Acad Sci U S A 106:6315-20. 2009
  5. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  6. doi Estimates of cancer incidence and mortality in Europe in 2008
    J Ferlay
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Eur J Cancer 46:765-81. 2010
  7. doi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
  8. ncbi Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Jerome Galon
    INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
    Science 313:1960-4. 2006
  9. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
  10. ncbi Identification of c-MYC as a target of the APC pathway
    T C He
    Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA
    Science 281:1509-12. 1998

Detail Information

Publications239 found, 100 shown here

  1. ncbi Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
    M M Borner
    Early Clinical Studies Group of The European Organization for Research and Treatment of Cancer, Belgium
    Eur J Cancer 38:349-58. 2002
    ..v. 5-FU/LV. Oral UFT/LV compares favourably with i.v. 5-FU/LV in terms of toxicity and patient's preference and leads to prolonged 5-FU exposure, which is comparable to continuous i.v. 5-FU treatment...
  2. ncbi KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
    J H J M van Krieken
    Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500, HB, The Netherlands
    Virchows Arch 453:417-31. 2008
    ..We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union...
  3. doi Role of miR-143 targeting KRAS in colorectal tumorigenesis
    X Chen
    Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China
    Oncogene 28:1385-92. 2009
    ..Taken together, the present study provides the first evidences that miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation...
  4. pmc Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer
    Veronica Rodilla
    Institut d Investigació Biomèdica de Bellvitge Gran Via km 2 7, Hospitalet and Institut Municipal d Investigacions Mèdiques Hospital del Mar, Dr Aiguader 88, 08003 Barcelona, Spain
    Proc Natl Acad Sci U S A 106:6315-20. 2009
    ..The Notch-specific genetic signature is sufficient to block differentiation and promote vasculogenesis in tumors whereas proliferation depends on both pathways...
  5. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy...
  6. doi Estimates of cancer incidence and mortality in Europe in 2008
    J Ferlay
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Eur J Cancer 46:765-81. 2010
    ..9%). The most common causes of death from cancer were lung cancer (342,000 deaths, 19.9% of the total), colorectal cancer (212,000 deaths, 12.3%), breast cancer (129,000, 7.5%) and stomach cancer (117,000, 6.8%)...
  7. doi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  8. ncbi Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Jerome Galon
    INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
    Science 313:1960-4. 2006
    ..In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies...
  9. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
    ..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
  10. ncbi Identification of c-MYC as a target of the APC pathway
    T C He
    Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA
    Science 281:1509-12. 1998
    ..These results provide a molecular framework for understanding the previously enigmatic overexpression of c-MYC in colorectal cancers...
  11. doi Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 28:4697-705. 2010
    ....
  12. ncbi MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
    I A Asangani
    Department of Experimental Surgery and Molecular Oncology of Solid Tumors, Medical Faculty Mannheim, University of Heidelberg, Germany
    Oncogene 27:2128-36. 2008
    ..This is the first study to show that Pdcd4 is negatively regulated by miR-21. Furthermore, it is the first report to demonstrate that miR-21 induces invasion/intravasation/metastasis...
  13. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  14. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  15. ncbi The consensus coding sequences of human breast and colorectal cancers
    Tobias Sjoblom
    Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Science 314:268-74. 2006
    ..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology...
  16. doi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  17. doi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  18. ncbi The genomic landscapes of human breast and colorectal cancers
    Laura D Wood
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 318:1108-13. 2007
    ..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
  19. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  20. ncbi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  21. doi Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    Eric Van Cutsem
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2011-9. 2011
    ..An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken...
  22. doi Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    Marc Peeters
    University Hospital Ghent, Ghent, Belgium
    J Clin Oncol 28:4706-13. 2010
    ..This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status...
  23. pmc Phenotypic characterization of human colorectal cancer stem cells
    Piero Dalerba
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 104:10158-63. 2007
    ..These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation...
  24. doi Colorectal cancer
    David Cunningham
    Gastrointestinal Unit, Royal Marsden Hospital National Health Service Foundation Trust, London and Surrey, UK
    Lancet 375:1030-47. 2010
    ..However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes...
  25. doi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  26. doi Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
    Zhaohui Huang
    Department of Pathology, Cancer Hospital, Fudan University, Shanghai, China
    Int J Cancer 127:118-26. 2010
    ..773 with 73.0% sensitivity and 79.7% specificity in discriminating advanced adenomas. Collectively, these data suggest that plasma miR-29a and miR-92a have strong potential as novel noninvasive biomarkers for early detection of CRC...
  27. pmc Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
    M P Coleman
    Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 377:127-38. 2011
    ..This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival...
  28. doi Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology
    Bernard Levin
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Gastroenterology 134:1570-95. 2008
    ..It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening...
  29. pmc Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
    Brenda K Edwards
    Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892 8315, USA
    Cancer 116:544-73. 2010
    ....
  30. ncbi Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  31. doi Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening
    E K O Ng
    Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Gut 58:1375-81. 2009
    ..MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC)...
  32. doi Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Nat Genet 42:973-7. 2010
    ..33 (rs4925386, OR = 0.93, P = 1.89 × 10⁻¹⁰). In addition to identifying new CRC risk loci, this analysis provides evidence that additional CRC-associated variants of similar effect size remain to be discovered...
  33. doi Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
    ..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab...
  34. doi A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    J Clin Oncol 27:672-80. 2009
    ..This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC...
  35. pmc Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    Timothy S Maughan
    School of Medicine, Cardiff University, Cardiff, UK
    Lancet 377:2103-14. 2011
    ....
  36. pmc Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21
    Albert Tenesa
    Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Edinburgh EH4 2XU, UK
    Nat Genet 40:631-7. 2008
    ..008) and rs4939827 (P < 0.009). Carrying all six possible risk alleles yielded OR = 2.6 (95% CI = 1.75-3.89) for CRC. These findings extend our understanding of the role of common genetic variation in CRC etiology...
  37. pmc Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
    Adam J Bass
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 43:964-8. 2011
    ..This study shows previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events...
  38. pmc Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Nat Genet 40:1426-35. 2008
    ..1 (rs10411210, RHPN2; P = 4.6 x 10(-9)) and 20p12.3 (rs961253; P = 2.0 x 10(-10)). These findings underscore the value of large sample series for discovery and follow-up of genetic variants contributing to the etiology of CRC...
  39. ncbi A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3
    Ian P M Tomlinson
    Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK
    Nat Genet 40:623-30. 2008
    ..3 (P = 3.3 x 10(-18) overall; P = 9.6 x 10(-17) replication), which tags a plausible causative gene, EIF3H. These data provide further evidence for the 'common-disease common-variant' model of CRC predisposition...
  40. doi Molecular genetics of colorectal cancer
    Eric R Fearon
    The Cancer Center, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, 48109 2200, USA
    Annu Rev Pathol 6:479-507. 2011
    ....
  41. ncbi Effector memory T cells, early metastasis, and survival in colorectal cancer
    Franck Pages
    INSERM UNITE 255, René Descartes Faculté de Médecine, Assistance Publique Hopitaux de Paris, Cordeliers Biomedical Research Center, University Paris 6, Paris, France
    N Engl J Med 353:2654-66. 2005
    ..The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown...
  42. doi Transcriptome profile of human colorectal adenomas
    Jacob Sabates-Bellver
    Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Mol Cancer Res 5:1263-75. 2007
    ....
  43. pmc The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
    Mark M Pomerantz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 41:882-4. 2009
    ..These data provide strong support for a biological mechanism underlying this non-protein-coding risk variant...
  44. doi Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer
    Francesca Molinari
    Institute of Pathology, Locarno, Switzerland
    Clin Cancer Res 17:4901-14. 2011
    ..We evaluated whether highly sensitive methods for KRAS investigation improve the accuracy of predictions of anti-EGFR MoAbs efficacy...
  45. ncbi Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial
    Wendy S Atkin
    Department of Surgery and Cancer, Imperial College London, London, UK
    Lancet 375:1624-33. 2010
    ..We tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years of age can substantially reduce colorectal cancer incidence and mortality...
  46. ncbi American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]
    Douglas K Rex
    Indiana University Medical Center, IU Hospital, Indianapolis 46202, USA
    Am J Gastroenterol 104:739-50. 2009
    ....
  47. doi Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer
    O Slaby
    Departments of Clinical and Experimental Pathology, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic
    Oncology 72:397-402. 2007
    ..MicroRNAs (miRNAs) are endogenously expressed regulatory noncoding RNAs. Previous, mainly preclinical studies showed altered expression levels of several miRNAs in CRC...
  48. ncbi A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk
    Peter Broderick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
    Nat Genet 39:1315-7. 2007
    ..Across the four sample sets, the association between rs4939827 and CRC was highly statistically significant (P(trend) = 1.0 x 10(-12))...
  49. doi Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011
    ....
  50. ncbi The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling
    Sari Tuupanen
    Department of Medical Genetics, Genome Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Nat Genet 41:885-90. 2009
    ..Our work provides evidence that the common CRC predisposition associated with 8q24 arises from enhanced responsiveness to Wnt signaling...
  51. doi Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer
    Paul Salama
    School of Surgery and Biostatistics Unit, Cancer Trials, Western Australian Institute for Medical Research, University of Western Australia, Australia
    J Clin Oncol 27:186-92. 2009
    ..To determine the prognostic significance of FOXP3(+) lymphocyte (Treg) density in colorectal cancer compared with conventional histopathologic features and with CD8(+) and CD45RO(+) lymphocyte densities...
  52. doi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  53. pmc Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer
    J Joshua Smith
    Department of Surgery, Vanderbilt Medical Center, Nashville, TN, USA
    Gastroenterology 138:958-68. 2010
    ..We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence...
  54. doi Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Woodville, SA 5011 Australia
    J Clin Oncol 29:2675-82. 2011
    ....
  55. ncbi The role of cyclooxygenases in inflammation, cancer, and development
    C S Williams
    Department of Medicine, The Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2279, USA
    Oncogene 18:7908-16. 1999
    ..The in vivo mechanism by which COX-2 affects tumor growth has not been determined. It is possible that both tumor and stromally derived COX-2 could influence tumor angiogenesis and/ or immune function...
  56. pmc Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
    Eddie K Abdalla
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg 239:818-25; discussion 825-7. 2004
    ..To examine recurrence and survival rates for patients treated with hepatic resection only, radiofrequency ablation (RFA) plus resection or RFA only for colorectal liver metastases...
  57. ncbi The ABC of APC
    N S Fearnhead
    Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Hum Mol Genet 10:721-33. 2001
    ..This review deals with our understanding to date of how mutations in the APC gene translate into changes at the protein level, which in turn contribute to the role of APC in tumorigenesis...
  58. ncbi Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
    L K Su
    Molecular Genetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD 21231
    Science 256:668-70. 1992
    ..Sequence comparison of mApc between normal and Min-affected mice identified a nonsense mutation, which cosegregated with the Min phenotype. This mutation is analogous to those found in FAP kindreds and in sporadic colorectal cancers...
  59. pmc Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis
    Francesc Balaguer
    Department of Internal Medicine, Division of Gastroenterology, Charles A Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas 75246, USA
    Cancer Res 70:6609-18. 2010
    ..Methylation silencing of miR-137 in colorectal adenomas suggests it to be an early event, which has prognostic and therapeutic implications...
  60. doi DNA methylation markers in colorectal cancer
    Myoung Sook Kim
    Department of Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 5M, Baltimore, MD, 21231, USA
    Cancer Metastasis Rev 29:181-206. 2010
    ..Therefore, the aim of this review is to understand DNA methylation as a driving force in colorectal neoplasia and its emerging value as a molecular marker in the clinic...
  61. ncbi Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology
    Bernard Levin
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:130-60. 2008
    ..It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening...
  62. doi Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk
    J Sainz
    Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
    Endocr Relat Cancer 18:265-76. 2011
    ..93, P trend=0.003) in the pooled sample. These findings implicate a role of ESR2 in the risk for developing CRC in women and suggest that HSD17B1, ABCB1, and SHBG genes may contribute to sex steroid-mediated effects on CRC development...
  63. ncbi Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force
    Evelyn P Whitlock
    Kaiser Permanente Center for Health Research, Portland, Oregon, USA
    Ann Intern Med 149:638-58. 2008
    ....
  64. doi Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer
    Minoru Toyota
    First Department of Internal Medicine, Cancer Research Institute, Sapporo Medical University, Sapporo, Japan
    Cancer Res 68:4123-32. 2008
    ..Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC...
  65. ncbi Hereditary colorectal cancer
    Henry T Lynch
    Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, Nebr 68178, USA
    N Engl J Med 348:919-32. 2003
  66. ncbi Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
    J R Jass
    Department of Pathology, McGill University, Montreal, Canada
    Histopathology 50:113-30. 2007
    ..This approach to the classification of CRC should accelerate understanding of causation and will impact on clinical management in the areas of both prevention and treatment...
  67. ncbi Folate and colorectal cancer: an evidence-based critical review
    Young In Kim
    Department of Medicine and Nutritional Sciences, Medical Sciences Building, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada
    Mol Nutr Food Res 51:267-92. 2007
    ..inhibitory effect whereas folate supplementation has a promoting effect on the progression of established colorectal neoplasms. In contrast, folate deficiency in normal colorectal mucosa appears to predispose it to neoplastic ..
  68. ncbi Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group
    David G Jayne
    Academic Unit of Surgery, St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 25:3061-8. 2007
    ..Few data are available on rectal cancer, and long-term data on survival and recurrence are now required...
  69. ncbi Colorectal cancer
    Jurgen Weitz
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Lancet 365:153-65. 2005
    ..Further clinical progress will largely depend on the broader implementation of multidisciplinary treatment strategies following the principles of evidence-based medicine...
  70. doi Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries
    Christina C Dahm
    Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    J Natl Cancer Inst 102:614-26. 2010
    ..Results of epidemiological studies of dietary fiber and colorectal cancer risk have not been consistent, possibly because of attenuation of associations due to measurement error in dietary exposure ascertainment...
  71. pmc Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Tumour Biol 31:89-96. 2010
    ....
  72. pmc Systemic treatment of colorectal cancer
    Brian M Wolpin
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:1296-310. 2008
    ....
  73. pmc Microsatellite instability in colorectal cancer
    C Richard Boland
    GI Cancer Research Laboratory, Division of Gastroenterology, Department of Internal Medicine, Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA
    Gastroenterology 138:2073-2087.e3. 2010
    ..Discovery of MSI in colorectal tumors has increased awareness of the diversity of colorectal cancers and implications for specialized management of patients...
  74. pmc Treatment in advanced colorectal cancer: what, when and how?
    I Chau
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 100:1704-19. 2009
    ..In this review, we have focused on the implications of these trial results on the everyday management decisions of treating advanced CRC...
  75. doi Trends in colorectal cancer test use in the medicare population, 1998-2005
    Anna P Schenck
    The Carolinas Center for Medical Excellence, Cary, North Carolina 27518 8598, USA
    Am J Prev Med 37:1-7. 2009
    ..Colorectal cancer (CRC) screening has been covered under the Medicare program since 1998. No prior study has addressed the question of the completeness of CRC screening in the entire Medicare cohort...
  76. ncbi The advanced adenoma as the primary target of screening
    Sidney J Winawer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, New York 10021, USA
    Gastrointest Endosc Clin N Am 12:1-9, v. 2002
    ....
  77. ncbi Critical evaluation of current treatments in metastatic colorectal cancer
    Alan Venook
    Division of Medical Oncology, Clinical Research Office, University of California Cancer Center, Box 1705, 1600 Divisadero, San Francisco, California 94115 1705, USA
    Oncologist 10:250-61. 2005
    ..This review discusses the role of the individual agents in the treatment of mCRC and identifies the most effective regimens...
  78. ncbi Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future
    Ami Sabharwal
    Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Expert Rev Anticancer Ther 7:477-87. 2007
    ..The evolution of chemotherapy use, current practice in the metastatic and adjuvant setting and possible future directions are discussed...
  79. ncbi CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
    Daniel J Weisenberger
    Department of Surgery, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90089 9176, USA
    Nat Genet 38:787-93. 2006
    ..Sporadic cases of mismatch repair deficiency occur almost exclusively as a consequence of CIMP-associated methylation of MLH1 . We propose a robust new marker panel to classify CIMP+ tumors...
  80. doi [Update S3-guideline "colorectal cancer" 2008]
    W Schmiegel
    Verantwortliche Institution Leitliniensekretariat Medizinische Klinik, Knappschaftskrankenhaus, Ruhr Universität Bochum und die AWMF im Auftrag der DGVS und der DKG Koordinatoren und Mitglieder der Konferenz siehe Anlage 1 3
    Z Gastroenterol 46:799-840. 2008
  81. pmc Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trial
    Thomas D Sequist
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA
    Arch Intern Med 169:364-71. 2009
    ..Screening reduces colorectal cancer mortality, but effective screening tests remain underused. Systematic reminders to patients and physicians could increase screening rates..
  82. ncbi Diabetes mellitus and risk of colorectal cancer: a meta-analysis
    Susanna C Larsson
    Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    J Natl Cancer Inst 97:1679-87. 2005
    ..To resolve these inconsistencies, we conducted a meta-analysis of published data on the association between diabetes and the incidence and mortality of colorectal cancer...
  83. ncbi The HER-2/neu oncogene in tumors of the gastrointestinal tract
    J S Ross
    Department of Pathology and Laboratory Medicine MC 81, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Cancer Invest 19:554-68. 2001
    ....
  84. ncbi Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer
    Qiong He
    Department of Human Anatomy and Neurobiology, Sun Yat Sen University, Guangzhou, Guangdong, P R China
    Cancer Genet Cytogenet 202:1-10. 2010
    ....
  85. ncbi Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors
    A Oberg
    Department of Surgical and Perioperative Sciences, Umea University Hospital, Sweden
    Int J Colorectal Dis 17:25-9. 2002
    ..To study whether there are differences in the immunohistochemical staining of CD8, CD45R0, and CD68 of immune cells in regional lymph node metastases from colorectal cancer that are of potential interest in prognostic prediction...
  86. pmc Distinct genetic alterations in colorectal cancer
    Hassan Ashktorab
    Department of Medicine and Cancer Center, Howard University, College of Medicine, Washington, DC, United States of America
    PLoS ONE 5:e8879. 2010
    ..In this study, we determined genomic copy number aberrations in sporadic CRC tumors from AAs, in order to investigate possible explanations for the observed disparities...
  87. doi Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue
    Wakkas Fadhil
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK
    J Clin Pathol 63:134-40. 2010
    ..Mutation detection in tumours will become increasingly important in pathological diagnosis as 'predictive' mutations are identified. A cheap and reliable test that works on formalin-fixed paraffin-embedded (FFPE) tissue is required...
  88. pmc Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer
    Sayaka Otake
    Division of Endoscopy, Yamagata University Hospital, 2 2 2 Iida nishi, Yamagata 990 9585, Japan
    World J Gastroenterol 16:1252-7. 2010
    ..To investigate the association between adiponectin levels and risk of colorectal adenoma and cancer (early and advanced)...
  89. doi Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes
    Atsushi Kaneda
    Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Meguro ku, Tokyo
    Cancer Sci 102:18-24. 2011
    ..Here we review and compare our recent study and reported CRC classification methods by DNA methylation information, and propose the use of two panels of methylation markers as CRC classifiers...
  90. ncbi Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population
    Ivona Hlavata
    Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic
    Oncol Rep 24:1347-53. 2010
    ..These results provide further evidence that interaction between metabolic gene variants contributes to colorectal carcinogenesis...
  91. ncbi Evidence for colorectal cancer screening
    Michael Bretthauer
    Centre for Colorectal Cancer Screening, The Cancer Registry of Norway, Oslo University Hospital, PO Box 5313 Majorstuen, N 0304 Oslo, Norway
    Best Pract Res Clin Gastroenterol 24:417-25. 2010
    ..FOBT and flexible sigmoidoscopy are the two CRC screening methods which have been tested in randomised trials and shown to reduce CRC mortality. These tests can be recommended for CRC screening...
  92. pmc Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas
    Xiang Jun Shen
    Center for Gastrointestinal Biology and Disease University of North Carolina at Chapel Hill, NC, USA
    Gut Microbes 1:138-47. 2010
    ..Extension of these findings could lead to strategies to manipulate the microbiota to prevent colorectal adenomas and cancer as well as to identify individuals at high risk...
  93. pmc Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells
    Avedis Kazanjian
    Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Gastroenterology 139:918-28, 928.e1-6. 2010
    ..We used genetic analyses of mice to determine whether Atoh1 mediates the effects of GSIs in normal and cancerous intestinal epithelia...
  94. pmc The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer
    Tarek M A Elsaba
    Division of Pathology, School of Molecular Medical Sciences, Queen s Medical Centre, University of Nottingham, Nottingham, United Kingdom
    PLoS ONE 5:e10714. 2010
    ..We conclude that CD133 expression in CRCs is associated with some features attributable to stemness and that there is plasticity of CD133 expression. Further studies are necessary to delineate the mechanistic basis of these features...
  95. pmc Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer
    Noriko Tanaka
    Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
    Am J Pathol 177:2731-40. 2010
    ..Our novel data suggest two distinct perturbations, resulting in differential locus-specific propensity of CpG methylation...
  96. pmc Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features
    Pei Woon Ang
    Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
    BMC Cancer 10:227. 2010
    ..In the present study we performed comprehensive DNA methylation profiling of CRC with the aim of characterizing CIMP subgroups...
  97. ncbi Risk factors for an adverse outcome in early invasive colorectal carcinoma
    Hideki Ueno
    Department of Surgery I, National Defense Medical College, Saitama, Japan
    Gastroenterology 127:385-94. 2004
    ..Various histologic findings exist for managing patients with malignant polyps. Our goal was to determine the criteria for a conservative approach to patients with locally excised early invasive carcinoma...
  98. doi Colorectal cancer: national and international perspective on the burden of disease and public health impact
    Ziad F Gellad
    Durham VA Medical Center and Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA
    Gastroenterology 138:2177-90. 2010
    ..Despite the strong impact of colorectal cancer on public health, there is cause for optimism and room for hope...
  99. pmc Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Int J Cancer 128:1080-94. 2011
    ..Despite its well-established role in carcinogenesis, CDKN2A (p16) promoter methylation or loss of expression in colorectal cancer is not independently associated with patient prognosis...
  100. ncbi Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype
    Pawel Karpinski
    Department of Genetics, Wroclaw Medical University, ul Marcinkowskiego 1, Wroclaw, Poland
    Cancer Epidemiol 34:338-44. 2010
    ..The aim of the present study was to evaluate whether polymorphisms in the genes encoding methyl-group metabolism pathway predispose to CIMP+ and/or CIMP- CRC...

Research Grants79

  1. DIET, GENETIC SUSCEPTIBILITY AND COLORECTAL ADENOMAS
    Loic Le Marchand; Fiscal Year: 2000
    ..in these foods, is determined by several polymorphic genes; thus, these genes may increase the risk of colorectal neoplasms. The susceptible phenotypes for most of these genes are several times more common in Japanese than ..
  2. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2003
    ..The antigens also may be of diagnostic value. ..
  3. Nanotechnology Linking Biomarkers with Cancer Behavior
    Shuming Nie; Fiscal Year: 2007
    ..abstract_text> ..
  4. Role of Angiogenesis in Colorectal Cancer using Transgenic Mouse Models
    LARRY ARTHUR; Fiscal Year: 2010
    ..These biomarkers could be molecular targets that could be beneficial for intervention, or correlative to the identified genes/proteins by microarrays or proteomic screening. ..
  5. Clinical Study of Disposition and Biological Activity of d-Limonene
    H H Sherry Chow; Fiscal Year: 2010
    ..This study will help evaluate the potentials of developing limonene as a breast cancer preventive agent. ..
  6. Clinical Study of Disposition and Biological Activity of d-Limonene
    H H Chow; Fiscal Year: 2009
    ..This study will help evaluate the potentials of developing limonene as a breast cancer preventive agent. ..
  7. DIET, GENETIC SUSCEPTIBILITY AND COLORECTAL ADENOMAS
    Loic Le Marchand; Fiscal Year: 1999
    ..in these foods, is determined by several polymorphic genes; thus, these genes may increase the risk of colorectal neoplasms. The susceptible phenotypes for most of these genes are several times more common in Japanese than ..
  8. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2000
    ..The antigens also may be of diagnostic value. ..
  9. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2001
    ..The antigens also may be of diagnostic value. ..
  10. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2002
    ..The antigens also may be of diagnostic value. ..
  11. Early life anthropometry, IGF pathway polymorphisms, and colorectal cancer risk
    Esther Wei; Fiscal Year: 2009
    ..g. childhood, young adulthood), with the ultimate goal of generating measurable improvements on the burden of colorectal cancer and other chronic diseases. ..
  12. Tea Modulation of Colon Carcinogenesis
    Michael Wargovich; Fiscal Year: 2010
    ..Because RXRa loss involves impairment of regulatory gene networks, the impact of green tea reversal of this transcription factor's loss is significant. ..
  13. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2004
    ....
  14. Early life anthropometry, IGF pathway polymorphisms, and colorectal cancer risk
    Esther Wei; Fiscal Year: 2010
    ..g. childhood, young adulthood), with the ultimate goal of generating measurable improvements on the burden of colorectal cancer and other chronic diseases. ..
  15. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ....
  16. MODULATION OF 5-FU PHARMACOLOGY BY PALA & DIPYRIDAMOLE
    Daniel Fernandes; Fiscal Year: 1992
    ..These results and experience in the use of these techniques with clinical samples will have applicability to other 5-FU-sensitive human neoplasms such as breast, head and neck and ovarian cancer...
  17. CORE--HUMAN TISSUE RESOURCE AND LOGISTICS
    Elizabeth Montgomery; Fiscal Year: 2002
    ....
  18. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2002
    ..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
  19. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2000
    ..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
  20. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 1999
    ..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
  21. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2001
    ..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
  22. MODULATION OF 5-FLUOROURACIL ACTIVITY IN COLON CARCINOMA
    Judith Belt; Fiscal Year: 1993
    ....
  23. Mechanisms of tumor suppressor gene reactivation in colon cancer by berries
    Li Shu Wang; Fiscal Year: 2010
    ..We now propose to evaluate the anthocyanins in berries for their ability to demethylate and reactivate tumor suppressor genes in colon cancer. ..
  24. METASTASIS SPECIFIC CARBOHYDRATE ANTIGENS
    Tatsuro Irimura; Fiscal Year: 1990
    ..Our long range goal is to determine how the production of sialyl-dimeric LeX antigen is regulated in situ, and to develop methods to reduce the amount, so that the tumor remains non-metastatic during the therapy...
  25. In Vivo Detection of Flat Colorectal Neoplasms with CT Colonography
    JANNE JOHANNES NAPPI; Fiscal Year: 2010
    ..substantially advance the clinical implementation of minimally invasive CTC-based population screening for colorectal neoplasms, thereby increasing patient adherence to colorectal screening guidelines, promoting early prevention of ..
  26. IMPROVING VIRTUAL COLONOSCOPY WITH COMPUTER DETECTION
    Peter Santago; Fiscal Year: 2001
    ..If VC with CAPD proves accurate and efficient in the diagnosis of colorectal polyps, it could evolve into a simple laboratory test, thereby meeting the demand for worldwide colorectal cancer screening. ..
  27. IMPROVING VIRTUAL COLONOSCOPY WITH COMPUTER DETECTION
    David Vining; Fiscal Year: 2000
    ..If VC with CAPD proves accurate and efficient in the diagnosis of colorectal polyps, it could evolve into a simple laboratory test, thereby meeting the demand for worldwide colorectal cancer screening. ..
  28. In Vivo Detection of Flat Colorectal Neoplasms with CT Colonography
    Janne Nappi; Fiscal Year: 2009
    ..substantially advance the clinical implementation of minimally invasive CTC-based population screening for colorectal neoplasms, thereby increasing patient adherence to colorectal screening guidelines, promoting early prevention of ..
  29. IMPROVING VIRTUAL COLONOSCOPY WITH COMPUTER DETECTION
    David Vining; Fiscal Year: 1999
    ..If VC with CAPD proves accurate and efficient in the diagnosis of colorectal polyps, it could evolve into a simple laboratory test, thereby meeting the demand for worldwide colorectal cancer screening. ..
  30. ISOLATION OF OLIGOSACCHARIDES--SUGAR-BINDING PROTEINS
    David Smith; Fiscal Year: 1990
    ..The long term benefits of this research will be to establish an important method for glycolipid structural analyses in the limited numbers of cells that will be encountered in studying glycoconjugate metabolism during embryogenesis...
  31. The Human Colorectal Instabilitome
    Stephen Meltzer; Fiscal Year: 2007
    ..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
  32. The Human Colorectal Instabilitome
    Stephen Meltzer; Fiscal Year: 2005
    ..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
  33. The Human Colorectal Instabilitome
    Stephen Meltzer; Fiscal Year: 2006
    ..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
  34. The Human Colorectal Instabilitome
    Stephen Meltzer; Fiscal Year: 2004
    ..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
  35. The Human Colorectal Instabilitome
    Stephen Meltzer; Fiscal Year: 2003
    ..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
  36. C/EBPbeta Isoform Function & Regulation by Tyrosine Kinases
    Cynthia Zahnow; Fiscal Year: 2007
    ..Functional characterization of the C/EBPB isoforms and the receptor tyrosine kinase pathways that regulate their expression will further our understanding of the molecular basis of mammary development and tumorigenesis. ..
  37. C/EBPbeta Isoform Function & Regulation by Tyrosine Kinases
    Cynthia Zahnow; Fiscal Year: 2009
    ..Functional characterization of the C/EBPB isoforms and the receptor tyrosine kinase pathways that regulate their expression will further our understanding of the molecular basis of mammary development and tumorigenesis. ..
  38. C/EBPbeta Isoform Function & Regulation by Tyrosine Kinases
    Cynthia Zahnow; Fiscal Year: 2005
    ..Functional characterization of the C/EBPB isoforms and the receptor tyrosine kinase pathways that regulate their expression will further our understanding of the molecular basis of mammary development and tumorigenesis. ..
  39. C/EBPbeta Isoform Function & Regulation by Tyrosine Kinases
    Cynthia Zahnow; Fiscal Year: 2006
    ..Functional characterization of the C/EBPB isoforms and the receptor tyrosine kinase pathways that regulate their expression will further our understanding of the molecular basis of mammary development and tumorigenesis. ..
  40. A Tumor Suppressor Function for the c-Fes Tyrosine Kinase in Colon Cancer
    THOMAS SMITHGALL; Fiscal Year: 2009
    ..If c-fes is a true tumor suppressor, then mice lacking c-fes function are expected to develop more severe disease in terms of tumor size, number, and invasiveness. ..
  41. A Tumor Suppressor Function for the c-Fes Tyrosine Kinase in Colon Cancer
    THOMAS EDWARD SMITHGALL; Fiscal Year: 2010
    ..If c-fes is a true tumor suppressor, then mice lacking c-fes function are expected to develop more severe disease in terms of tumor size, number, and invasiveness. ..
  42. Nanotechnology Linking Biomarkers with Cancer Behavior
    Shuming Nie; Fiscal Year: 2004
    ..abstract_text> ..
  43. Nanotechnology Linking Biomarkers with Cancer Behavior
    Shuming Nie; Fiscal Year: 2006
    ..abstract_text> ..
  44. Nanotechnology Linking Biomarkers with Cancer Behavior
    Shuming Nie; Fiscal Year: 2005
    ..abstract_text> ..
  45. Metabolism and Carcinogenicity of Heterocyclic Amines
    TERRY ZENSER; Fiscal Year: 2007
    ..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
  46. Metabolism and Carcinogenicity of Heterocyclic Amines
    TERRY ZENSER; Fiscal Year: 2006
    ..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
  47. Metabolism and Carcinogenicity of Heterocyclic Amines
    TERRY ZENSER; Fiscal Year: 2003
    ..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
  48. Metabolism and Carcinogenicity of Heterocyclic Amines
    TERRY ZENSER; Fiscal Year: 2004
    ..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
  49. Metabolism and Carcinogenicity of Heterocyclic Amines
    TERRY ZENSER; Fiscal Year: 2005
    ..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
  50. DEVELOPING VIRTUAL COLONOSCOPY FOR CANCER SCREENING
    JEROME LIANG; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  51. DEVELOPING VIRTUAL COLONOSCOPY FOR CANCER SCREENING
    JEROME LIANG; Fiscal Year: 2005
    ....
  52. DEVELOPING VIRTUAL COLONOSCOPY FOR CANCER SCREENING
    JEROME LIANG; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  53. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2004
    ....
  54. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2002
    ....
  55. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2005
    ....
  56. Computerized Detection of Polyps in CT Colonography
    Hiroyuki Yoshida; Fiscal Year: 2010
    ..abstract_text> ..
  57. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2006
    ....
  58. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2003
    ....
  59. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2010
    ..In this proposal, we plan to determine how APC plays a role in the pathogenesis of MDS and t-MDS/t-AML, ultimately leading to new effective therapeutic strategies for these diseases. ..
  60. DIETARY PLANT PHENOLICS--EFFECT ON COLONIC BIOMARKERS
    STEVEN SHIFF; Fiscal Year: 1999
    ..These may be integral processes by which NSAIDs inhibit the development of colorectal neoplasms. It is conceivable that other colon cancer chemopreventive agents share these potential mechanisms of ..
  61. DIETARY PLANT PHENOLICS--EFFECT ON COLONIC BIOMARKERS
    STEVEN SHIFF; Fiscal Year: 1999
    ..These may be integral processes by which NSAIDs inhibit the development of colorectal neoplasms. It is conceivable that other colon cancer chemopreventive agents share these potential mechanisms of ..
  62. STAT1 Activation and HPP1 Tumor Suppression
    David Shibata; Fiscal Year: 2010
    ..is a recently identified gene that was initially discovered by virtue of its significant downregulation in colorectal neoplasms derived from patients with Hyperplastic Polyposis...
  63. NLRP12 Regulation of COX-2 in Colitis and Colon Cancer Development
    JUSTIN ETHAN WILSON; Fiscal Year: 2010
    ..Successful completion of these goals may support the addition of NLRP12 to the list of NLR genes currently being targeted by multiple pharmaceutical companies. ..
  64. Folate, 1-Carbon Nutrients, Gene Variants & Colon Cancer
    David Hunter; Fiscal Year: 2003
    ..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
  65. STAT1 Activation and HPP1 Tumor Suppression
    David Shibata; Fiscal Year: 2009
    ..is a recently identified gene that was initially discovered by virtue of its significant downregulation in colorectal neoplasms derived from patients with Hyperplastic Polyposis...
  66. Microsatellite Instability and the DNA Mismatch Repair System
    John M Carethers; Fiscal Year: 2011
    ..in the germline of familial colon cancer (Lynch syndrome) as well as inactivated in up to 20% of sporadic colorectal neoplasms due to hypermethylation of one of the components of DNA MMR...
  67. Folate, 1-Carbon Nutrients, Gene Variants & Colon Cancer
    David Hunter; Fiscal Year: 2004
    ..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
  68. Folate, 1-Carbon Nutrients, Gene Variants & Colon Cancer
    David Hunter; Fiscal Year: 2007
    ..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
  69. Folate, 1-Carbon Nutrients, Gene Variants & Colon Cancer
    David Hunter; Fiscal Year: 2005
    ..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
  70. Folate, 1-Carbon Nutrients, Gene Variants & Colon Cancer
    David Hunter; Fiscal Year: 2006
    ..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
  71. The biology of gastrin-ferric ion complexes
    GRAHAM BALDWIN; Fiscal Year: 2006
    ..Recognition that metal ions are essential for the biological activity of NAGs may permit the development of novel therapies for colon cancer. ..
  72. The biology of gastrin-ferric ion complexes
    GRAHAM BALDWIN; Fiscal Year: 2007
    ..Recognition that metal ions are essential for the biological activity of NAGs may permit the development of novel therapies for colon cancer. ..
  73. The biology of gastrin-ferric ion complexes
    GRAHAM BALDWIN; Fiscal Year: 2009
    ..Recognition that metal ions are essential for the biological activity of NAGs may permit the development of novel therapies for colon cancer. ..
  74. CHARACTERIZATION OF GENES FROM THE FAP LOCUS
    KENNETH KINZLER; Fiscal Year: 1992
    ..The combination of the above studies should provide important insights into the role of APC and MCC in colorectal tumorigenesis...
  75. MARKERS FOR METASTATIC PHENOTYPE IN COLORECTAL CANCER
    Stanley Hamilton; Fiscal Year: 1990
    ..5) To analyze using appropriate statistical methods the data for the various markers in relation to each other as well as to the pathologic features of the colorectal carcinomas, the presence of metastases, and patient survival...
  76. CHARACTERIZATION OF GENES FROM THE FAP LOCUS
    KENNETH KINZLER; Fiscal Year: 1993
    ..The combination of the above studies should provide important insights into the role of APC and MCC in colorectal tumorigenesis...
  77. Emory-GA Tech Nanotechnology Center for Personalized an*
    Shuming Nie; Fiscal Year: 2007
    ....